BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 35782895)

  • 41. Low penetrance alleles as risk modifiers in familial and sporadic breast cancer.
    Esteban Cardeñosa E; de Juan Jiménez I; Palanca Suela S; Chirivella González I; Segura Huerta A; Santaballa Beltran A; Casals El Busto M; Barragán González E; Fuster Lluch O; Bermúdez Edo J; Bolufer Gilabert P
    Fam Cancer; 2012 Dec; 11(4):629-36. PubMed ID: 22926736
    [TBL] [Abstract][Full Text] [Related]  

  • 42. BRCA1 promoter methylation in peripheral blood DNA of mutation negative familial breast cancer patients with a BRCA1 tumour phenotype.
    Snell C; Krypuy M; Wong EM; ; Loughrey MB; Dobrovic A
    Breast Cancer Res; 2008; 10(1):R12. PubMed ID: 18269736
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Evaluation of expression profiles of microRNAs and two target genes, FOXO3a and RUNX2, effectively supports diagnostics and therapy predictions in breast cancer.
    Jurkovicova D; Magyerkova M; Sestakova Z; Copakova L; Bella V; Konecny M; Krivjanska M; Kulcsar L; Chovanec M
    Neoplasma; 2016; 63(6):941-951. PubMed ID: 27596294
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Epigenetic inactivation of BRCA1 through promoter hypermethylation in ovarian cancer progression.
    Wang YQ; Yan Q; Zhang JR; Li SD; Yang YX; Wan XP
    J Obstet Gynaecol Res; 2013 Feb; 39(2):549-54. PubMed ID: 23006047
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Methylation of the BRCA1 promoter in peripheral blood DNA is associated with triple-negative and medullary breast cancer.
    Gupta S; Jaworska-Bieniek K; Narod SA; Lubinski J; Wojdacz TK; Jakubowska A
    Breast Cancer Res Treat; 2014 Dec; 148(3):615-22. PubMed ID: 25376744
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Discovery of potential serum and urine-based microRNA as minimally-invasive biomarkers for breast and gynecological cancer.
    Ritter A; Hirschfeld M; Berner K; Jaeger M; Grundner-Culemann F; Schlosser P; Asberger J; Weiss D; Noethling C; Mayer S; Erbes T
    Cancer Biomark; 2020; 27(2):225-242. PubMed ID: 32083575
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Methylation of BRCA1 promoter region is associated with unfavorable prognosis in women with early-stage breast cancer.
    Hsu NC; Huang YF; Yokoyama KK; Chu PY; Chen FM; Hou MF
    PLoS One; 2013; 8(2):e56256. PubMed ID: 23405268
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The risk of primary and contralateral breast cancer after ovarian cancer in BRCA1/BRCA2 mutation carriers: Implications for counseling.
    Vencken PM; Kriege M; Hooning M; Menke-Pluymers MB; Heemskerk-Gerritsen BA; van Doorn LC; Collée MM; Jager A; van Montfort C; Burger CW; Seynaeve C
    Cancer; 2013 Mar; 119(5):955-62. PubMed ID: 23165859
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Constitutive
    Azzollini J; Pesenti C; Pizzamiglio S; Fontana L; Guarino C; Peissel B; Plebani M; Tabano S; Sirchia SM; Colapietro P; Villa R; Paolini B; Verderio P; Miozzo M; Manoukian S
    Cancers (Basel); 2019 Jan; 11(1):. PubMed ID: 30634417
    [TBL] [Abstract][Full Text] [Related]  

  • 50. BRCA1 Promoter Methylation and Clinicopathological Characteristics in Sporadic Breast Cancer Patients in Indonesia.
    Harahap WA; Sudji IR; Nindrea RD
    Asian Pac J Cancer Prev; 2018 Sep; 19(9):2643-2649. PubMed ID: 30256562
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Investigation of BRCAness associated miRNA-gene axes in breast cancer: cell-free miR-182-5p as a potential expression signature of BRCAness.
    Darbeheshti F; Kadkhoda S; Keshavarz-Fathi M; Razi S; Bahramy A; Mansoori Y; Rezaei N
    BMC Cancer; 2022 Jun; 22(1):668. PubMed ID: 35715772
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Epigenetic silencing of BRCA1 gene associated with demographic and pathologic factors in sporadic breast cancer: a study of an Indian population.
    Singh AK; Pandey A; Tewari M; Shukla HS; Pandey HP
    Eur J Cancer Prev; 2011 Nov; 20(6):478-83. PubMed ID: 21572332
    [TBL] [Abstract][Full Text] [Related]  

  • 53. MicroRNA in breast cancer: The association with BRCA1/2.
    Petrovic N; Davidovic R; Bajic V; Obradovic M; Isenovic RE
    Cancer Biomark; 2017; 19(2):119-128. PubMed ID: 28128741
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Significance of BRCA1 expression in breast and ovarian cancer patients with brain metastasis - A multicentre study.
    Szarszewska M; Markowska A; Jach R; Marszałek A; Filas V; Bednarek W; Olejek A; Tomczak P; Sajdak S; Nowak-Markwitz E; Jaszczyńska-Nowinka K; Stanisławiak-Rudowicz J; Gryboś A; Chudecka-Głaz A; Gryboś M; Adamska K; Ramlau R; Markowska J; Knapp P
    Adv Med Sci; 2019 Sep; 64(2):235-240. PubMed ID: 30822630
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Promoter methylation and expression changes of
    Li Q; Wei W; Jiang YI; Yang H; Liu J
    Oncol Lett; 2015 Apr; 9(4):1807-1813. PubMed ID: 25789047
    [No Abstract]   [Full Text] [Related]  

  • 56. BRCA1 promoter methylation of normal breast epithelial cells as a possible precursor for BRCA1-methylated breast cancer.
    Otani Y; Miyake T; Kagara N; Shimoda M; Naoi Y; Maruyama N; Shimomura A; Shimazu K; Kim SJ; Noguchi S
    Cancer Sci; 2014 Oct; 105(10):1369-76. PubMed ID: 25155055
    [TBL] [Abstract][Full Text] [Related]  

  • 57. CASP8 D302H polymorphism delays the age of onset of breast cancer in BRCA1 and BRCA2 carriers.
    Palanca Suela S; Esteban Cardeñosa E; Barragán González E; de Juan Jiménez I; Chirivella González I; Segura Huerta A; Guillén Ponce C; Martínez de Dueñas E; Montalar Salcedo J; Castel Sánchez V; Bolufer Gilabert P;
    Breast Cancer Res Treat; 2010 Jan; 119(1):87-93. PubMed ID: 19214744
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Reproductive factors as risk modifiers of breast cancer in
    Park B; Hopper JL; Win AK; Dowty JG; Sung HK; Ahn C; Kim SW; Lee MH; Lee J; Lee JW; Kang E; Yu JH; Kim KS; Moon BI; Han W; Noh DY; Park SK;
    Oncotarget; 2017 Nov; 8(60):102110-102118. PubMed ID: 29254229
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Promoter methylation of BRCA1 in triple-negative breast cancer predicts sensitivity to adjuvant chemotherapy.
    Xu Y; Diao L; Chen Y; Liu Y; Wang C; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Deng D; Narod SA; Xie Y
    Ann Oncol; 2013 Jun; 24(6):1498-505. PubMed ID: 23406733
    [TBL] [Abstract][Full Text] [Related]  

  • 60. BRCA1 promoter methylation in peripheral blood cells is associated with increased risk of breast cancer with BRCA1 promoter methylation.
    Iwamoto T; Yamamoto N; Taguchi T; Tamaki Y; Noguchi S
    Breast Cancer Res Treat; 2011 Aug; 129(1):69-77. PubMed ID: 20882403
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.